Premium
Bone Marrow Granulomas Possibly Associated with Amiodarone
Author(s) -
Yamreudeewong Weeranuj,
McIntyre William W.,
Sun Tsieh J.,
Ranelli Paul L.
Publication year - 2000
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.20.9.855.35204
Subject(s) - amiodarone , medicine , atrial fibrillation , bone marrow suppression , bone marrow , adverse effect , granuloma , cardiology , refractory (planetary science) , anesthesia , surgery , chemotherapy , pathology , physics , astrobiology
Amiodarone is a class III antiarrhythmic agent that is effective in treating different types of cardiac dysrhythmias. It was approved only for treatment of life‐threatening ventricular dysrhythmias refractory to other therapy; however, its use for atrial dysrhythmias such as atrial fibrillation is well accepted. Adverse effects associated with amiodarone include pulmonary, hepatic, thyroid, ocular, and neurologic toxicities. Our patient experienced intermittent fever, night sweats, and fatigue while taking the drug for treatment of atrial fibrillation. Bone marrow biopsy showed granuloma formation after 17 months of therapy with amiodarone. Amiodarone was discontinued due to significant hypotension and shortness of breath. To our knowledge, this is the third case report of granuloma formation in bone marrow possibly associated with this agent.